Drug delivery system targeting advanced hepatocellular carcinoma: Current and future

2016 ◽  
Vol 12 (4) ◽  
pp. 853-869 ◽  
Author(s):  
Xue Zhang ◽  
Huei Leng Helena Ng ◽  
Aiping Lu ◽  
Congcong Lin ◽  
Limin Zhou ◽  
...  
2020 ◽  
Author(s):  
Sanxiu He ◽  
Shaorong Tian ◽  
Xin Le ◽  
Jialin Chen ◽  
Hongyi Chen ◽  
...  

Abstract Background: Currently, the treatment for advanced hepatocellular carcinoma (HCC) is extremely limited. Ginsenoside Rg3, ganoderma lucidum polysaccharide, and Oridonin have shown great potential in anti-tumor therapy in previous studies, but low bioavailability and poor solubility seriously hinder their clinical application. Hence, new strategy for liver cancer are urgently needed. Methods: Cell viability, cell proliferation, cell migration, colony formation, tubule formation, sphere formation, and flow cytometry were used to assess the effect of a new drug, RGO-SMEDDS, (self-microemulsifying drug delivery system comprising of Rg3, ganoderma lucidum polysaccharide, and Oridonin) on HCC. Specific anti-tumor mechanisms of RGO-SMEDDS were investigated by western blot, qRT-PCR, and immunohistochemistry. Xenografts and staining with hematoxylin and eosin were used to assess the effects of RGO-SMEDDS on tumorigenesis in vivo.Results: We developed a self-microemulsifying drug delivery system (RGO-SMEDDS) for these three plant monomers. Treatment with RGO-SMEDDS resulted in induction of G2/M phase arrest and apoptosis, inhibition of migration and invasion, and suppression of cell proliferation, both in vitro and in vivo. Furthermore, RGO-SMEDDS restored immune function by suppressing the production of immunosuppressive cytokine and M2-polarized macrophages, reduced angiogenesis by down-regulation of vascular endothelial growth factor and its receptor, and attenuated stemness of HCC by inhibiting EGFR/AKT/GSK-3α/β signaling pathways. In addition to excellent anti-tumor effects, RGO-SMEDDS showed considerable safety in acute toxicity tests.Conclusion: RGO-SMEDDS exerted significant anti-tumor effects by reducing angiogenesis, remodeling immune microenvironments, and promoting apoptosis, without obvious toxicities. With these attributes RGO-SMEDDS is a promising therapy for the treatment of hepatocellular carcinoma.


2018 ◽  
Vol 54 (87) ◽  
pp. 12353-12356 ◽  
Author(s):  
Hardev Singh ◽  
Seo Jin Kim ◽  
Dong Hoon Kang ◽  
Hye-Ri Kim ◽  
Amit Sharma ◽  
...  

Herein, we explore glycyrrhetinic acid (GA) as an active targeting ligand for hepatocellular carcinoma (HCC) using a small molecule approach.


2012 ◽  
Vol 56 ◽  
pp. S115
Author(s):  
A. Mazzocca ◽  
F. Baldassarre ◽  
V. Vergaro ◽  
S. Leporatti ◽  
G. Ciccarella ◽  
...  

2012 ◽  
Vol 5 ◽  
pp. BCI.S9824
Author(s):  
Kei Shimoda ◽  
Manabu Hamada ◽  
Masaharu Seno ◽  
Tadakatsu Mandai ◽  
Hiroki Hamada

Chemo-enzymatic synthesis of glycolyl-ester-linked taxol-glucose conjugate, ie, 7-glycolyltaxol 2′- O-α-D-glucoside, was achieved by using α-glucosidase as a biocatalyst. The water-solubility of 7-glycolyltaxol 2′- O-α-D-glucoside (21 μM) was 53 fold higher than that of taxol. The hepatitis B virus envelope L particles (bio-nanocapsules) are effective for delivering 7-glycolyltaxol 2′- O-α-D-glucoside to human hepatocellular carcinoma NuE cells.


Sign in / Sign up

Export Citation Format

Share Document